A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients With 1-4 Brain Metastases.

Trial Profile

A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients With 1-4 Brain Metastases.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Brain metastases
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 14 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 18 Aug 2016 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.
    • 18 Aug 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top